ASX 200 shares soared 2.6% to an intraday peak of 8,804 points in morning trading on Tuesday.

Leading the market today are Guzman Y Gomez Ltd (ASX: GYG) shares, up 18%, and Nextdc Ltd (ASX: NXT), up 12%.

However, some ASX shares are bucking the trend.

Here are six stocks that hit 52-week lows today.

Sonic Healthcare Ltd (ASX: SHL)

Sonic Healthcare is one of several ASX healthcare shares trading at multi-year lows these days.

The sector faces multiple headwinds, including currency changes, US tariffs, and higher labour costs and other expenses.

The Sonic Healthcare share price fell to a decade-low of $18.88 today.

This ASX healthcare share has fallen 13% in the year to date (YTD) and 21% over the past year.

Ord Minnett has a hold rating on Sonic Healthcare with a 12-month share price target of $24.

Stockland Corp Ltd (ASX: SGP)

The Stockland share price fell to a 52-week low of $4.01 today.

Stockland shares are down 30% YTD.

In a separate article, my colleague Aaron has delved into the reasons this ASX property share has tanked in 2026.

Macquarie has just reiterated its buy rating on Stockland shares with a target price of $4.42.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price fell to a record low of $3.13 on Tuesday.

Endeavour shares have tumbled 14% YTD.

Citi recently downgraded this ASX consumer staples share to a hold rating.

The broker reduced its 12-month target from $4.30 to $3.70.

Atlas Arteria Group Ltd (ASX: ALX)

The Atlas Arteria share price fell to a nine-year low of $4.21 today.

Shares in the toll roads operator have fallen 13% YTD.

Last week, Morgan Stanley maintained its hold rating on Atlas Arteria shares.

The broker reduced its share price target from $5.06 to $4.96.

Lendlease Group (ASX: LLC)

The Lendlease share price dropped to an all-time low of $3.10 on Tuesday.

The ASX real estate share has fallen 39% in 2026.

Today, Macquarie reiterated its buy rating with a 12-month price target of $4.99.

Healius Ltd (ASX: HLS)

The Healius share price dropped to a record low of 51 cents today.

The ASX healthcare share has declined 43% YTD.

Goldman Sachs reiterated its sell rating on Healius shares last month.

The broker lowered its price target from 66 cents to 57 cents.

The post 6 ASX shares hitting 52-week lows amid today's market rally appeared first on The Motley Fool Australia.

Today, 307 ASX shares are rising, 48 are steady, and 145 are falling.

Among the fallers are these four companies that have hit 52-week low share prices today.

Are they a buy, hold, or sell?

Let's ask the experts.

Fletcher Building Ltd (ASX: FBU)

The Fletcher Building share price fell to a 52-week low of $2.42 on Tuesday.

This ASX industrials share is down 21% in the year to date (YTD), and down 17% over the past 12 months.

On The Bull this week, Blake Halligan from Catapult Wealth revealed a sell rating on the building materials and services provider.

He said the 1H FY26 report "highlighted ongoing pressure", with net debt remaining elevated and the company cutting capital expenditure.

Halligan said:

Earnings before interest and tax from continuing operations before significant items was $NZ145 million, which was marginally below expectations. The company has announced the sale of its construction division for $NZ315.6 million.

However, broader conditions in New Zealand remain subdued, and a meaningful earnings recovery isn't expected until calendar year 2027. With limited catalysts and no dividend support, better opportunities present elsewhere.

Guzman Y Gomez Ltd (ASX: GYG) 

The Guzman Y Gomez share price sank to a record low of $15.48 in earlier trading.

The ASX consumer discretionary share has fallen 26% YTD and tumbled 50% over 12 months.

Morgans has a buy rating on the stock but recently slashed its 12-month price target from $32.30 to $24.

The broker said:

If it was just about Australia, GYG would be doing just fine right now. But it's not just about Australia.

Unfortunately, the pace of network expansion in the US so far has been pedestrian and the restaurants it has opened have lost more money than expected.

GYG has a bit to prove, but we can be certain it is going to give it all it's got to ultimately realise its growth ambitions.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price fell to a record low of $3.28 today.

Endeavour shares have declined 10% YTD and have fallen 14% over the past 12 months.

Last week, Citi downgraded the ASX consumer staples share to a hold rating.

The broker also reduced its 12-month price target from $4.30 to $3.70.

Healius Ltd (ASX: HLS)

The Healius share price dropped to a record low of 52 cents today.

This ASX healthcare share has crashed 42% in the YTD and 63% over 12 months.

Healius is one of many ASX healthcare shares trading at multi-year lows today.

The sector is facing multiple headwinds due to currency shifts, US tariffs, and higher labour costs and other expenses.

Healius, a pathology services provider, reported improved financial metrics but continuing losses overall in its 1H FY26 report.

The company reported an underlying loss of $11 million for 1H FY26, which was an improvement on its $20.2 million loss for 1H FY25.

Morgans has a hold rating on Healius shares with a 12-month target of 80 cents.

The broker commented:

While management maintained FY26 earnings in line with consensus and operational discipline is improving, sustainable earnings leverage remains an open question and dependent on execution.

The post 4 ASX shares at 52-week lows: Buy, hold, or sell? appeared first on The Motley Fool Australia.

The ASX All Ords hit an all-time high of 9,436.2 points on Friday, the final day of earnings season, and fell 0.13% yesterday.

Today, the market is substantially lower as investors continue to weigh how the US and Israel attack on Iran will affect world order.

Energy is the only sector in the green today as oil and gas prices continue to climb on expectations of disrupted global supply.

Meanwhile, three ASX All Ords shares have hit 52-week lows today.

Are they a buying opportunity, or is it best to steer clear?

Let's defer to the experts.

4 ASX All Ords shares slumping to 52-week lows

HMC Capital Ltd (ASX: HMC)

This ASX All Ords financial share fell to a 52-week low of $2.54 on Tuesday.

That's a 72% deterioration over 12 months, but Morgans sees the upside.

The broker retained its buy rating on HMC Capital shares after reviewing the company's 1H FY26 report.

In a note, Morgans commented:

We still see value in HMC, with our market-to-market NTA at c.$2.30 per share, or c.$3.00 when we factor in our valuation for the listed co-investments (HDN, HCW, DGT), while the c.$60m of recurring funds management EBITDA adds additional value.

Morgans lowered its 12-month price target from $4.85 to $4.45.

Healius Ltd (ASX: HLS)

The Healius share price tumbled to a 52-week trough of 66 cents today.

This ASX All Ords healthcare share has halved in value over the past 12 months.

Morgans reiterated its hold rating after reviewing the pathology services provider's 1H FY26 report.

The broker commented:

While management maintained FY26 earnings in line with consensus and operational discipline is improving, sustainable earnings leverage remains an open question and dependent on execution.

The broker gives the ASX All Ords healthcare share a 12-month target of 80 cents.

DigiCo Infrastructure REIT (ASX: DGT)

This ASX All Ords real estate investment trust (REIT) fell to a 52-week low of $1.93 on Tuesday.

The data centre specialist has lost more than 55% of its value over the past year.

Morgans is optimistic, however, after going over the company's 1H FY26 results.

The broker commented:

DGT continues to trade at a c.50% discount to NAV of A$4.62/security, yet that NAV does not yet reflect the full value of the 88MW SYD1 expansion, which management estimates will deliver a further c.A$1.50/security of NAV uplift at a targeted 15% yield on cost.

Acknowledging the share price weakness, we continue to see the opportunity in DGT, retaining our Buy rating with a $4.15/sh price target.

Beacon Lighting Group Ltd (ASX: BLX)

This ASX All Ords consumer discretionary share reached a 52-week low of $2.02 today.

That's a 41% fall over 12 months.

However, Morgans upgraded Beacon Lighting from accumulate to buy on the back of its 1H FY26 report.

The broker commented:

BLX 1H26 result was weaker than expected, driven by softer sales in both retail and trade, which has tempered expectations of a meaningful recovery in the 2H.

Whilst earnings recovery is likely longer dated, we see long-term opportunity in trade, store network growth, and margin expansion as the cycle turns.

The broker lowered its share price target from $3.80 to $3.20.

The post 4 ASX All Ords shares at 52-week lows. Should you buy? appeared first on The Motley Fool Australia.

Healius shares are down 2.45% today to 71.7 cents.

That follows a 6.75% fall on results day and a further 3.29% decline in the prior session. The stock is now trading at a record low and is down around 20% since the start of 2026.

While parts of the business showed improvement, investors remain focused on the company's ongoing losses.

Let's take a closer look at what was reported.

Revenue rises but losses remain

For the 6 months to 31 December 2025, Healius reported revenue of $688.1 million, up 3.8% on the prior corresponding period.

Underlying EBITDA increased 13.1% to $122.2 million. The company also delivered underlying EBIT of $7.9 million, an improvement on the loss recorded a year earlier.

The core pathology division generated revenue of $666.3 million, up 3.5%, with EBIT improving to $5.2 million.

Agillex Biolabs, which provides specialist laboratory services to pharmaceutical and biotechnology companies, was a stronger performer. Revenue increased 16% to $21.8 million, and EBIT rose 145.5% to $2.7 million.

Despite these improvements, Healius reported a statutory net loss after tax of $30.4 million, reflecting restructuring costs, digital program expenses, and finance costs.

The company also confirmed it will not pay an interim dividend.

Balance sheet and cost savings in focus

Healius ended the half with net cash of $11.6 million. It held $51.6 million in cash and had $40 million in drawn debt.

Management said cost reduction initiatives are continuing. The company is targeting $15 million to $20 million in annual support cost savings, with $10.7 million in annualised savings already delivered in the first half.

The group also confirmed its major digital program has been completed, with future technology spend expected to return to more typical levels.

Healius expects full-year earnings to be in line with current market expectations and continues to target high single-digit EBIT margins by June 2027.

Investors remain unconvinced

Although some operating metrics improved, the market is focused on the continued statutory loss and the uncertainty around the pace of recovery.

With the share price now at a record low, investor confidence remains weak. The market is looking for clearer evidence that revenue growth and cost reductions can deliver consistent profits.

Foolish Takeaway

Healius is delivering some improvement at an operational level, particularly in pathology and Agillex. However, the company remains loss-making on a statutory basis and is not returning cash to shareholders.

Until profits stabilise and become consistent, the share price may remain under pressure despite signs of progress.

The post Healius shares hit record low after half-year loss. Here's what happened appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Baby Bunting Group Ltd (ASX: BBN)

The Baby Bunting share price is down 3.5% to $2.30. This morning, analysts at Morgans reaffirmed their hold rating on this baby products retailer's shares with a trimmed price target of $2.60. The broker said: "BBN's 1H26 pro-forma NPAT was up 4.1% yoy to $5.0m which was in the middle of guidance range ($4.5-$5.5m) driven by comps sales growth, gross margin expansion offset by higher costs. Nine stores have been refurbished to the new store design, and have performed strongly, sales up 25%, which is at the upper end of guidance range of 15-25%. FY26 NPAT guidance has been narrowed to $17.5-$19.5m (was $17-20m). We have made minor changes to forecasts. We have a $2.60 target price (was $2.70) Hold recommendation retained."

Capstone Copper Corp (ASX: CSC)

The Capstone Copper share price is down 18% to $12.78. This follows the release of the copper miner's guidance for 2026. Capstone Copper expects consolidated copper production of between 200,000 and 230,000 tonnes in 2026. This is broadly in line with 2025 levels. Management also advised that it expects consolidated C1 cash costs of US$2.45 to US$2.75 per payable pound of copper in 2026. This is an increase compared to 2025, primarily due to modest inflation and lower-grade ore at Mantos Blancos and Pinto Valley driven by mine sequencing.

Healius Ltd (ASX: HLS)

The Healius share price is down 11% to 72.7 cents. This morning, this healthcare company released its half-year results and reported a 3.8% increase in group revenue to $688.1 million and underlying EBIT of $7.9 million. The latter was up from a loss of $2.7 million a year ago. While management expects to achieve earnings in line with consensus estimates in FY 2026, it warned that its revenue and profitability will be skewed towards the second half. This is due to both the timing of cost savings and normal volume seasonality factors. The market appears sceptical that it will deliver on this guidance.

Suncorp Group Ltd (ASX: SUN)

The Suncorp share price is down 5% to $15.19. Investors have been selling this insurance giant's shares following the release of its half-year results. Suncorp reported a net profit after tax of $263 million, which is down heavily from $1.1 billion a year earlier. The company's CEO, Steve Johnston, said: "While Suncorp's 1H26 reported profits and shareholder returns have been challenged by an elevated level of natural hazard costs and lower investment returns over the half, our underlying business remains resilient as we continue to deliver on our strategic imperatives and drive good momentum leading into the second half of the financial year."

The post Why Baby Bunting, Capstone Copper, Healius, and Suncorp shares are falling today appeared first on The Motley Fool Australia.

What did Argo Investments Limited report?

• Half-year profit: $130.8 million, up from $121.2 million last year
• Earnings per share: 17.2 cents, up from 15.9 cents
• Interim dividend: 18.5 cents per share (fully franked), up 8.8%
• Management expense ratio: 0.14%, improved from 0.15%
• Grossed-up annual yield: 6.1% based on the last closing share price

What else do investors need to know?

Argo's investment revenue from its portfolio was flat over the half, but profit was lifted by trading and options income. The company has boosted its fully franked dividend by 37.5% over the past five years, maintaining 100% franking even throughout volatile market conditions.

During the period, Argo made some notable investment changes, adding CSL Ltd (ASX: CSL), Amcor (ASX: AMC), Worley Ltd (ASX: WOR), Rio Tinto Ltd (ASX: RIO), BHP Group Ltd (ASX:BHP) , Generation Development Group Ltd (ASX: GDG), and Clarity Pharmaceuticals Ltd (ASX: CU6), while selling all shares in Healius Ltd (ASX: HLS) and GPT Group (ASX: GPT). The total number of portfolio stocks decreased slightly from 85 to 83.

What did Argo Investments management say?

Managing Director Jason Beddow said:

We considered it appropriate to meaningfully increase the interim dividend. The Board is committed to sustainably growing Argo's fully franked dividends.

What's next for Argo Investments?

Looking ahead, Argo noted the outlook remains highly uncertain given ongoing geopolitical risks and shifting monetary policy, including higher Australian interest rates. The team highlighted Australia's structural advantages, particularly in resources and critical minerals.

Argo plans to keep its diversified approach, spanning more than 80 ASX-listed companies. The company says it aims to provide shareholders with reliable income and long-term capital growth, even through volatile markets.

Argo Investments share price snapshot

Over the past 12 months, Argo Investments shares have risen 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement

The post Argo Investments reports record profit and dividend appeared first on The Motley Fool Australia.

Will the market be able to bounce back from this on Thursday? Here are five things to watch:

ASX 200 expected to fall again

The Australian share market looks set to fall again on Thursday following a mixed night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 40 points or 0.45% lower this morning. In late trade in the United States, the Dow Jones is down 0.2%, the S&P 500 is flat, and the Nasdaq is up 0.55%.

Oil prices rise

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a decent session on Thursday after oil prices pushed higher overnight. According to Bloomberg, the WTI crude oil price is up 0.3% to US$60.33 a barrel and the Brent crude oil price is up 0.6% to US$64.79 a barrel. A large decline in US stockpiles was behind this rise.

Annual general meetings

A number of ASX 200 shares are holding their annual general meetings today and could provide the market with trading updates. Among the companies holding events are corporate travel specialist Corporate Travel Management Ltd (ASX: CTD), healthcare company Healius Ltd (ASX: HLS). Retail giant JB Hi-Fi Ltd (ASX: JBH), and Bunning and Kmart owner Wesfarmers Ltd (ASX: WES).

Gold price fall

It could be a poor session for ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) on Thursday after the gold price tumbled into the red. According to CNBC, the gold futures price is down 0.75% to US$3,952.3 an ounce. Traders were selling gold after the US Federal Reserve cast doubts on a December rate cut.

Buy Woolworths shares

Now could be the time to buy Woolworths Group Ltd (ASX: WOW) shares according to analysts at Bell Potter. This morning, the broker has upgraded the supermarket giant's shares to a buy rating with a $30.70 price target. It said: "We upgrade from Hold to Buy. WOW has been in an earnings downgrade cycle for two years and this looks to be coming to an end. Trading at a reasonable ~12% discount to COL and ~14% discount to its historical FWD EV/EBITDA, there is now a reasonable valuation arbitrage, just as the underperformance in Australian Food looks to be bottoming and out-of-home indicators improving (the latter a positive for B2B)."

The post 5 things to watch on the ASX 200 on Thursday appeared first on The Motley Fool Australia.

Since 30 June, the S&P/ASX 200 Health Care Index (ASX: XHJ) has lost 4.1% of its value while the ASX 200 has lifted 4.6%.

FY25 was no party either, with ASX 200 healthcare shares falling 5.99% in value while delivering just a 1.38% dividend.

By contrast, the ASX 200 lifted 9.97% and delivered a 3.84% dividend on top.

In this article, we reveal three ASX healthcare shares with sell ratings, and explain why the experts are calling time on these stocks.

Analysts call time on 3 ASX healthcare shares

Pro Medicus Ltd (ASX: PME)

Pro Medicus provides medical imaging software and services to hospitals and healthcare organisations around the world.

The ASX 200 healthcare darling closed the session yesterday at $302.38 per share, down 0.35%.

Peter Day of Sequoia Wealth Management has a sell rating on Pro Medicus shares.

Day said the company delivered FY25 results that were broadly in line with expectations.

On The Bull this week, Day summarised the key data:

Revenue from ordinary activities of $213 million was up 31.9 per cent on the prior corresponding period.

Net profit of $115.2 million was up 39.2 per cent.

During the year, Pro Medicus announced $520 million in new contracts.

The Pro Medicus share price has risen from $176.88 on 7 April to $302.38 now.

Day said:

We retain our sell rating as we believe the company's valuation is stretched.

Our target price is $220, up from $165.

Cochlear Ltd (ASX: COH)

Cochlear develops, manufactures, and supplies hearing implants.

Morgans recommends that investors trim their position in this ASX 200 healthcare share after reviewing the company's FY25 report.

The broker said the FY25 result was "below expectations" and at the low end of guidance.

It said net profit was impacted by compressing margins and modest sales growth.

The broker raised its 12-month share price target to $299.54.

The Cochlear share price closed at $301.01 yesterday, down 0.41%.

Looking ahead to FY26, Morgans commented:

While Nexa's US launch should support CI demand through FY26, we caution against assuming uplift similar to prior product transitions, as Nexa is aimed at workflow efficiency and patient convenience rather than a step-change in hearing performance, so more of an evolutionary not revolutionary refinement that may take time to translate into material volume or margin gains.

Healius Ltd (ASX: HLS)

Healius is a diagnostic pathology company.

The Healius share price leapt 12% to 94 cents per share yesterday.

Investors may be buying the dip on this ASX healthcare share, with no fresh price-sensitive news to explain the rise.

Healius shares took a 14% beating after the company released its FY25 results last Thursday.

Since then, the stock has roared back, rising 33.5% over the past three trading days.

Tony Paterno of Ord Minnett has a sell rating on this ASX healthcare share.

Paterno summarised the FY25 results (courtesy The Bull):

The company generated revenue of $1.34 billion in fiscal year 2025, up 5.7 per cent on the prior corresponding period.

However, underlying earnings before interest and tax of $17.1 million were down 27.2 per cent.

The company reported a net loss after tax of $151.2 million.

Paterno points out that Healius shares closed at $1.60 on 7 May, so there's been a 41% decline since then.

He concluded:

In our view, other companies offer better returns and brighter prospects.

The post Analysts reveal 3 ASX healthcare shares to sell appeared first on The Motley Fool Australia.

Shares in the ASX 200 healthcare stock ended Thursday at $0.70 per share, down by 14% from yesterday's closing price of $0.81.

Not only that, but the group's share price tumbled to a new 52-week low in today's session.

It is fair to say that both Healius and its shareholders endured a challenging FY25.

Let's take a closer look at what happened.

Difficult year

FY25 can be characterised as a transitional year for Healius.

The ASX 200 healthcare stock launched a new strategy focused on simplifying its business model after selling its Lumus Imaging business in May.

The sale helped the company improve its balance sheet by generating cash proceeds of $822 million.

Soon after, the board of directors committed to paying a fully franked special dividend of 41.3 cents per share. This payout equates to about $300 million.

New strategic direction

Healius' new strategy seeks to boost revenues and cut costs.

This new direction comes in response to challenging market conditions in the pathology sector, characterised by inflationary pressures and high labour costs.

The ASX 200 healthcare stock has already launched a labour optimisation program to help address this issue.

Healius also seeks to improve the volume and quality of its revenue by providing better services for patients and referrers.

This includes diversifying its revenue away from the Medicare Benefits Schedule (MBS).

Furthermore, the group is aiming to modernise its collection centre and laboratory operations through technological digitisation.

Higher margin products and services are also a priority.

FY25 in review

All up, the ASX 200 healthcare stocks reported a soft set of numbers for FY25.

Revenue of $1.34 billion grew by 5.7% year-on-year.

However, underlying operating earnings (EBITDA) of $239.3 million declined by 4.0%. Underling EBIT of $17.1 million fared worse, tumbling by 27.2%.

These outcomes stemmed from a muted performance in the company's dominant pathology segment.

Here, revenue of $1.30 billion grew by 6% from twelve months prior.

Pathology EBITDA of $244.2 million fell by 3%, with EBIT of $28.2 million clocking in 15.3% lower.

Labour costs remained elevated at almost half of revenue.

In turn, the pathology EBIT margin came in at 2.2% for FY25 but improved to 3.6% in the second half of the year.

On the bottom line, Healius ended FY25 with a net cash position of $57.2 million, aided by the proceeds from the Lumus sale.

Moving forward

Management noted that its focus for FY26 remains diversifying the company's revenue mix and trimming labour costs.

That said, it projects revenue growth in FY26 to be consistent with the growth shown in the second half of FY25.

Pathology revenue jumped by 5.1% in the second half of FY25 despite a modest volume increase of 1.6%.

Meanwhile, labour costs in FY26 are projected to remain flat.

The ASX 200 healthcare stock expects to achieve high single digit EBIT margins at the tail end of the fiscal year.

The post Why did this ASX 200 healthcare stock crash 14% yesterday? appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Goodman Group (ASX: GMG)

The Goodman share price is down over 2% to $35.32. Investors have been selling this industrial property giant's shares following the release of its full year results. Although Goodman reported strong growth in FY 2025 and is guiding to similar growth in FY 2026, the latter appears to have been a touch short of the market's expectations. Goodman is guiding to 9% earnings per share growth, whereas the consensus estimate was for 11% growth. Though, it is worth noting that Goodman is usually conservative with its guidance early in the financial year.

Healius Ltd (ASX: HLS)

The Healius share price is down 16% to 68.2 cents. This follows the release of the healthcare company's FY 2025 results. Healius posted a 5.7% increase in group revenue to $1.34 billion but a 27% decline in underlying EBIT to $17.1 million. On a reported basis, the company recorded a net loss of $151.2 million. Unsurprisingly, the Healius board decided against paying a final dividend.

IPH Ltd (ASX: IPH)

The IPH share price is down almost 20% to $4.49. This morning, this intellectual property services company released its full year results and revealed a 16.5% increase in revenue to $710.3 million and a 7.3% lift in underlying NPATA to $120.6 million. However, this growth was driven by acquisitions. It notes that on a like for like currency adjusted basis, revenue was flat on the prior year and underlying EBITDA was down 3.9%. Nevertheless, this didn't stop IPH from increasing its dividend again.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price is down 14% to $24.76. This is despite the healthcare company reporting a much-improved performance in FY 2025. Sonic Healthcare posted an 8% increase in revenue to $9,645 million and a 7% lift in net profit to $514 million. Management also revealed that an "even stronger performance [is] expected in FY2026, with EPS growth of up to 19%." It seems that the market was expecting even stronger growth from Sonic Healthcare in the new financial year.

The post Why Goodman, Healius, IPH, and Sonic Healthcare shares are falling today appeared first on The Motley Fool Australia.

But that was just the warm-up.

In the weeks ahead, dozens of ASX-listed companies across all sectors will deliver their outcomes for the full financial year, or for the six-month period ending in June.

And that includes some of the biggest and most closely watched ASX 200 healthcare stocks.

Kicking off proceedings was Resmed CDI (ASX: RMD) – a specialist in sleep disorder treatment – with Friday's fourth quarter and full year results.

In brief, the group's FY25 revenue jumped by 10% from a year ago, which helped to fuel a 19% increase in operating profit.

The market appeared to respond favourably, with the company's share price lifting by 1% from Thursday's close to hit record highs in Friday's trading.

ResMed's share price has now risen by 16% since the start of the year, ending last week at $42.88 per share.

In comparison, the All Ordinaries Index (ASX: XAO) is up by 5.3% over the same period.

But how will the rest of the healthcare sector perform during reporting season?

Watch this space

The list below presents 10 ASX 200 healthcare stocks set to report in August.

But before diving in, there's a few important notes to consider.

Firstly, some of these dates may change as companies conclude their number crunching.

In addition, this is not a complete list. More healthcare businesses will also be revealing their results in the coming weeks.

And one final thing.

For investors tracking other sectors, reporting dates for ten leading ASX 200 mining stocks can be found here.

Similarly, a schedule for six prominent ASX 200 energy stocks is located here.

FY25 reporting dates – ASX 200 healthcare stocks

• Thursday 14 August – Pro Medicus Ltd (ASX: PME): This imaging software provider gets the ball rolling.
• Friday 15 August – Cochlear Ltd (ASX: COH): An iconic Aussie business specialising in implantable hearing solutions.
• Tuesday 19 August – CSL Ltd (ASX: CSL): The healthcare sector's biggest company and third largest on the ASX.
• Friday 22 August – A four-company event:
  • Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH): Manufacturer of respiratory care products.
  • Healius Ltd (ASX: HLS): Diagnostic services provider.
  • Telix Pharmaceuticals Ltd (ASX: TLX): Growing diagnostic radiopharmaceuticals business.
  • Sonic Healthcare Ltd (ASX: SHL): Diversified healthcare provider.
• Monday 25 August – A double announcement:
  • Ansell Ltd (ASX: ANN): Protective personal equipment manufacturer.
  • Polynovo Ltd (ASX: PNV): Medical device developer.
• Thursday 28 August – Ramsay Health Care Ltd Fully Paid Ord. Shrs (ASX: RHC): Owner and operator of hospitals and health care clinics across 11 countries.

The post CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August appeared first on The Motley Fool Australia.

Compared to large-cap stocks, small-cap stocks have higher growth potential. Due to their size, they can grow much more rapidly. On the ASX, a small-cap stock is typically defined as a company with a market capitalisation of less than $2 billion.

It's much easier for an ASX small-cap company with a low market share to double in size than a larger company that's already a market leader. 

In a 17 July research note, Macquarie Group Ltd (ASX: MQG) named 3 ASX small-cap companies in the healthcare sector with between 56% and 130% upside. 

What are they?

Healius Ltd (ASX: HLS)

Healius provides specialty diagnostic services to Australian consumers and practitioners. It has 3 operating segments: Pathology, Imaging, and Others. 

Over the past 5 years, Healius shares have taken a hit, declining 74%.

However, Macquarie is forecasting that the stock can turn around. 

In its upcoming results, the broker will look for commentary on base business trends, cost growth/margins, and progress on the T27 strategy.

Macquarie currently has a price target of $1.20 on Healius shares. 

At the time of writing, Healius shares are changing hands for $0.77. This suggests 56% upside from here over the next 12 months.

Monash IVF (ASX: MVF)

Monash IVF operates 13 clinics and is Australia's second-largest IVF provider

Two unfortunate incidents have weighed heavily on Monash IVF's share price this year. For the year to date, Monash IVF shares are down 40%.

Macquarie believes it has been oversold. Monash IVF shares have already risen 41% since their 52-week low of $0.54 in April. However, the broker believes they remain undervalued and can rebound significantly.

Macquarie currently has a price target of $1.30 on Monash IVF shares.

At the time of writing, Monash IVF shares are changing hands for $0.76. This suggests 79% upside from here over the next 12 months, including capital growth and dividends.

Monash IVF currently offers an attractive dividend yield of 6.75%.

Polynovo Ltd (ASX: PNV)

PolyNovo develops and commercialises innovative medical devices using its patented NovoSorb technology. NovoSorb is used in the treatment of burns and surgical wounds. 

Polynovo shares are down 45% over the past 5 years.

However, Macquarie believes there is material upside from here.

The broker is forecasting 2H25 revenue of $71.7m, and will be looking for management commentary regarding its BARDA trial and performance of its new MTX product when it releases its upcoming results.

Macquarie currently has a price target of $2.80 on Polynovo shares. At the time of writing, Polonovo shares are changing hands for $1.22, suggesting a 130% upside over the next 12 months.

The post Broker tips these 3 ASX small-cap healthcare stocks to rise 56%, 79% and 130% appeared first on The Motley Fool Australia.

Recent trends have seen big returns in sectors like tech and financials. 

If you were exposed to these sectors before the last couple of years, you would likely be sitting pretty today. 

One important piece of data I am aware of, is Australia's ageing population. 

Looking ahead

Data from the Australian Bureau of statistics shows in 2020, there were an estimated 4.2 million older Australians (aged 65 and over) – comprising 16% of the total Australian population. 

In the next 30 years, this number is projected to increase to more than 20%. 

Essentially, one in five Australians will be over the age of 65. 

Why is that the case?

Firstly, advances in healthcare, medical technology, and living standards mean Australians are living longer. 

Secondly, the baby boomer generation (born between 1946 and 1964) is progressively reaching retirement age.

As this large demographic group moves into the 65+ age bracket, it significantly increases the overall percentage of older Australians.

What does this mean for investors?

When we project this data for the long term, it makes me aware of the enormous demand for several key sectors in the decades ahead. 

One key area that is set to benefit is the healthcare sector. As we age, the demand for healthcare services increases. 

Some key ASX listed stocks that could be set to benefit include: 

• CSL Ltd (CSL): Global leader in blood plasma, vaccines, and biotherapies.
• Cochlear Ltd (COH): Implants for hearing loss, common in older adults.
• ResMed Inc (ASX: RMD): Sleep apnea devices, increasingly used by ageing populations.
• Ramsay Health Care Ltd (ASX: RHC): Operates private hospitals across Australia and globally.
• Healius Ltd (ASX: HLS) and Sonic Healthcare Ltd (ASX: SHL) Pathology and diagnostic services.

Other key companies to monitor are those in the pharmaceuticals & biotechnology space, aged care & retirement living and wealth management. 

These areas all play an important role in caring for older Australians.

Which ASX ETFs give exposure to these sectors?

While these individual stocks may have plenty of upside, there are thematic ASX ETFs that combine hundreds of these options into one fund. 

An ageing population is not a unique problem only here in Australia.

In fact, the World Health Organisation recently revealed life expectancy at birth reached 73.3 years in 2024, an increase of 8.4 years since 1995.

The number of people aged 60 and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030.

Global X S&P Biotech ETF (ASX: CURE)

This fund seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

It is made up of roughly 124 holdings, with no individual company representing more than 3.3% of the fund.

iShares Global Healthcare ETF (ASX: IXJ)

The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large, mid or small-capitalisation stocks.

Its largest holdings include Eli Lilly, Johnson and Johnson and ABBVIE Inc.

It also includes a small exposure to Australian companies in this sector. 

BetaShares Global Healthcare ETF – Currency Hedged (ASX: DRUG)

DRUG WTF aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. 

At the time of writing it provides access to 59 of the world's leading healthcare companies, such as Johnson & Johnson, Pfizer and Roche, in one trade.

The post The long game: ASX ETFs to target amidst an ageing population appeared first on The Motley Fool Australia.

That's because S&P Dow Jones Indices has just announced changes in the S&P/ASX Indices that will be effective prior to the open of trading on June 23 following the June quarterly review.

Let's see which ASX 20, ASX 50, ASX 100, and ASX 200 shares are being impacted by the changes.

ASX 20 index

There has been one change to the exclusive ASX 20 index.

That change will see the under pressure James Hardie Industries plc (ASX: JHX) dumped from the index later this month after falling 30% from its 52-week high amid concerns over its proposed acquisition of AZEK Company Inc (NYSE: AZEK).

It will be replaced by supply chain solutions company Brambles Ltd (ASX: BXB). Its shares are up over 17% since the start of the year.

ASX 50 index

There was also one change to the illustrious ASX 50 index.

This will see gold miner Evolution Mining Ltd (ASX: EVN) replace the embattled lithium miner Pilbara Minerals Ltd (ASX: PLS) when the ASX 50 index rebalances later this month.

ASX 100 index

S&P Dow Jones Indices will be making two changes to the ASX 100 index at the June quarterly rebalance.

Heading out of the index this month will be uranium miner Paladin Energy Ltd (ASX: PDN) and fuel retailer Viva Energy Group Ltd (ASX: VEA).

Their market capitalisations have shrunk over the past 12 months after their shares dropped 53% and 40%, respectively.

Replacing them in the index will be gold miner Perseus Mining Ltd (ASX: PRU), which is up 64% since last year, and Pinnacle Investment Management Group Ltd (ASX: PNI), which is up more than 50% over the same period.

ASX 200 index

Finally, the benchmark ASX 200 index is making two changes at this quarterly rebalance.

Heading out of the index will be struggling healthcare company Healius Ltd (ASX: HLS) and coal miner Stanmore Resources Ltd (ASX: SMR).

It seems that heavy declines have led to their market capitalisations falling below what is required for inclusion in the benchmark index. Healius shares are down almost 40% and Stanmore Resources shares are down over 40% since this time last year.

Replacing them in the ASX 200 index will be shipbuilder Austal Ltd (ASX: ASB) and furniture retailer Nick Scali Limited (ASX: NCK). Their shares are up 157% and 34%, respectively, over the past 12 months.

The post Here are the ASX 20, ASX 50, ASX 100, and ASX 200 shares being added and kicked out of their indices appeared first on The Motley Fool Australia.

Will the market be able to bounce back from this on Tuesday? Here are five things to watch:

ASX 200 expected to rebound

The Australian share market is expected to rise on Tuesday after two positive sessions in a row on Wall Street. According to the latest SPI futures, the ASX 200 is poised to open the day 23 points or 0.27% higher. In the United States, the Dow Jones was flat, the S&P 500 climbed 0.1%, and the Nasdaq pushed 0.3% higher. On Friday, all three indices charged higher in response to jobs data.

Quarterly rebalance

Austal Ltd (ASX: ASB) and Nick Scali Limited (ASX: NCK) shares will be on watch on Tuesday after the shipbuilder and furniture retailer were added to the benchmark ASX 200 index at the latest quarterly rebalance. They will be taking the place of healthcare company Healius Ltd (ASX: HLS) and coal miner Stanmore Resources Ltd (ASX: SMR) when the index rebalances on 23 June.

Oil prices rise

It could be a good session for ASX 200 energy shares Santos Ltd (ASX: STO) and Karoon Energy Ltd (ASX: KAR) after oil prices rose overnight. According to Bloomberg, the WTI crude oil price is up 1.2% to US$65.37 a barrel and the Brent crude oil price is up 0.9% to US$67.09 a barrel. This was driven by optimism over US-China trade talks in London.

Buy Develop Global shares

The team at Bell Potter thinks that Develop Global Ltd (ASX: DVP) shares could be in the buy zone. This morning, the broker has retained its buy rating on the miner and underground mining contractor's shares with an improved price target of $5.00 (from $4.00). It said: "DVP has demonstrated impressive execution of workflows to date to enable a timely and within-budget restart of operations at its flagship Woodlawn operation. We expect the successful ramp-up of Woodlawn production by 1H FY26 to drive a transformation in the company's EPS outlook in FY26."

Gold price edges higher

ASX 200 gold shares Evolution Mining Ltd (ASX: EVN) and Regis Resources Limited (ASX: RRL) could have a relatively subdued session after the gold price edged higher overnight. According to CNBC, the gold futures price is up slightly to US$3,347.1 an ounce. Traders were buying gold ahead of the US-China trade talks.

The post 5 things to watch on the ASX 200 on Tuesday appeared first on The Motley Fool Australia.

Meanwhile, the experts say investors should sell these three constituents of the benchmark index.

Here's why.

Experts say these 3 ASX 200 shares are a sell

JB Hi-Fi Ltd (ASX: JBH)

JB Hi-Fi shares are trading at $109.85 apiece on Tuesday, up 1.79% for the day so far and up 88% over the past 12 months.

That big gain is precisely why Jabin Hallihan of Family Financial Solutions has a sell rating on the ASX 200 consumer retail share.

Hallihan told The Bull:

In our view, the company's valuation appears stretched and offers limited upside from these levels.

Given the stock's premium pricing, we suggest investors consider selling a parcel of JBH shares …

Hallihan said JB Hi-Fi's Australian sales rose by 6.5% and New Zealand sales jumped 17.5% in the third quarter of FY25.

The broker suggests investors take their recent capital gains and invest in Kogan.com Ltd (ASX: KGN) shares instead.

He notes that Kogan is "expanding market share at a more attractive valuation".

Kogan shares are steady at $3.95 apiece at the time of writing, down 9% over the past year.

REA Group Ltd (ASX: REA)

The REA share price is $242.94, up 1.1% on Tuesday and 32% over the past year.

REA Group operates Australia's biggest online property classifieds business.

Hallihan reckons this ASX 200 communications share is a sell, too.

He comments:

The stock looks overpriced.

We believe the valuation is stretched in a subdued residential property market.

We would recommend investors consider cashing in some gains to reduce risk.

Hallihan noted that REA generated revenue of $374 million in the third quarter of FY25, up 12% on the prior corresponding period (pcp).

Total revenue in the financial year to 31 March was $1.247 billion, up 18%.

Healius Group Ltd (ASX: HLS)

This ASX 200 healthcare share is trading at 87 cents, down 1.14% today and down 35% over the past 12 months.

Christopher Watt of Bell Potter has a sell rating on Healius shares.

He's concerned about the diagnostic pathology company's earnings targets.

Watt said:

After recently completing the sale of Lumas Imaging, HLS paid shareholders a special fully franked special dividend totalling about $300 million or 41.3 cents a share.

In our view, earnings before interest and tax targets in fiscal year 2027 imply overly ambitious cost-outs.

The return on capital in fiscal year 2026 is modest.

In our view, other companies offer better returns and brighter prospects moving forward.

The post Sell alert! Brokers say pull the plug on these 3 ASX 200 shares appeared first on The Motley Fool Australia.

Yesterday we covered five of the month's top performers.

Today, we profile five of the biggest laggards.

Now, do take note that just because a stock has had a bad month doesn't mean it can't come roaring back. Any more than a stock which has had a banner month can't be in for a rough patch ahead.

With that said, here are five ASX 200 shares that took a steep fall in the month just past.

ASX 200 shares catching headwinds in May

The first ASX 200 share that lost a lot of ground in May is Insignia Financial Ltd (ASX: IFL).

Shares in the financial services company closed out April trading for $3.79 and finished May at $3.36 apiece. That saw the Insignia Financial share price down 11.4% over the month.

That loss, and then some, can be attributed to 14 May. Insignia shares closed down 15.8% on the day after the company reported that Bain Capital was not going forward with its acquisition proposal. Insignia said it remains hopeful that a similarly priced takeover offer ($5.00 per share) from CC Capital Partners will proceed.

The second ASX 200 share best avoided in May was IDP Education Ltd (ASX: IEL).

Shares in the language testing and student placement provider ended April at $8.86 and closed out May trading for $7.80. This saw the IDP Education share price down 12.0% over the month.

IDP has been struggling amid increasingly restrictive policies on foreign student enrolments in its core markets of the United Kingdom, the United States, Canada, and Australia. Policy uncertainty in those nations remains a concern for investors heading into June.

Which brings us to the third ASX 200 share that took a big tumble in May, Pilbara Minerals Ltd (ASX: PLS).

Shares in the Aussie lithium miner closed April at $1.51 and closed May trading for $1.24 each. That puts the Pilbara Minerals share price down 17.9% for the month.

There was no fresh news out from Pilbara over the month, with most of the selling pressure likely driven by a roughly 10% decline in lithium prices over the month.

Moving on to the fourth ASX 200 share that took a beating in May, we have Nufarm Ltd (ASX: NUF).

Shares in the agricultural chemical and seed technology company closed April at $3.85 and finished May at $2.38 apiece. This saw the Nufarm share price down a precipitous 38.2% in May.

The Nufarm share price closed down 30.1% on 21 May following the release of the company's half-year results. Investors were hitting their sell buttons after Nufarm reported a 39% year-on-year decline in statutory net profit after tax to $29.8 million for the half. Underlying net profit after tax was down 24% to $38.5 million.

Leading the way down

Rounding off with the ASX 200 share posting the biggest loss in May, we turn to Healius Ltd (ASX: HLS).

Shares in the pathology and imaging provider finished April at $1.46 and closed out May trading for 88 cents apiece. That puts the Healius share price down 39.7% for the month.

But Healius investors won't have felt nearly as much of that loss as that figure suggests.

That's because the ASX 200 share paid a whopping 41.3 cents per share fully franked special dividend on 23 May. And much of the retrace in the share price was due to the stock trading ex-dividend on 9 May, when shares closed down 25.0% for the day.

So, if we add that 41.3 cents per share dividend back into the closing price at the end of May, we get an adjusted closing price of $1.293 per share. Which means investors holding the stock for the entire month will have realised a significantly lesser loss of 11.5%.

The post The 5 worst performing ASX 200 shares in May unmasked appeared first on The Motley Fool Australia.

The All Ordinaries Index (ASX: XAO) opened 0.29% higher on Thursday.

In a recent note to investors, Macquarie Group Ltd (ASX: MQG) has updated its position and target price on three ASX All Ords stocks in the healthcare sector. It expects some share prices could increase as much as 30-50%.

Integral Diagnostics Ltd (ASX: IDX)

Integral Diagnostics provides diagnostic imaging services to general practitioners, medical specialists, and allied professionals. It operates under three core brands: Lake Imaging, South Coast Radiology, and Global Diagnostics. 

Company shares crashed 30% in February this year when the business recorded a statutory loss of $0.4 million in its half-year results. Investors were strongly disappointed, and many offloaded their shares. 

Integral Diagnostics attributed the loss to higher-than-expected clinical staff cost inflation, particularly in two remote regional areas. 

Since its crash, the share price has slowly gained ground and is trading 15.02% higher today at $2.45 per share.

But Macquarie thinks there is room for a much stronger recovery. In its note, the broker revealed its outperform rating at a $3.20 target price on the stock. This indicates a potential 30.61% upside from today's price.

Although Macquarie also notes that key downsides to its thesis relate to weaker-than-expected volume growth and/or operating cost growth ahead of expectations. It also points to less-than-expected cost synergies from the potential merger as another downside.

Australian Clinical Labs Ltd (ASX: ACL)

Australian Clinical Labs is a leading private provider of pathology services in Australia. 

The company's share price suffered a similar fate to Integral Diagnostics when it plummeted 16.21% in late February. The drop followed a cybersecurity incident that exposed sensitive patient data. 

At the same time, the company's market value also declined as investors responded to the company skipping full-year guidance and potentially not paying a final dividend, despite strong first-half profits, the AFR reported.

Today, the shares are trading at $2.935 a piece, down 1.84% for the day. The share price is still up 33.41% for the year.

Macquarie is neutral on the stock. In its investor note, it has assigned a $3.15 target price, indicating a potential 7.32% upside.

"The key downside to our thesis and Neutral recommendation is slower-than-expected recovery in base pathology volumes, with upside being additional synergies providing cost out and a faster recovery in base pathology volume," Macquaire said.

Healius Ltd (ASX: HLS)

Healius is an Australian healthcare company that provides pathology, diagnostic imaging, and related services to consumers and healthcare professionals. It has a large network of laboratories, collection centres, and imaging centres across Australia.

The Healius share price remained steady throughout the first quarter of the year, thanks to strong H1 2025 results.

But its share price has spiraled in May. Shares are trading at $0.9125 today, down 42.96% since 7 May.

There has been no news out of the healthcare company, but it appears that investors are concerned about the state of Australia's healthcare sector.

Healthscope went into administration this week.

Macquarie is neutral on the stock, but expects a strong recovery as investors regain confidence. The broker has placed a $1.40 target price on shares, up from $1.38 previously, which would represent a potential 53.42% increase from today's trading price.

"The key risks to our earnings forecasts, target price and rating primarily relate to variation in base business activity (pathology, diagnostic imaging), operating expense growth relative to our expectations and the final outcomes associated with the divestment of Lumus Imaging," it said.

The post Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Aspen Group Ltd (ASX: APZ)

The Aspen Group share price is down 2% to $3.39. This morning, this affordable living developer released a presentation ahead of its appearance at a conference. Although the company spoke positively about its medium term outlook, investors may have been betting on a guidance upgrade and were disappointed that one didn't happen.

Healius Ltd (ASX: HLS)

The Healius share price is down 5% to 90.7 cents. This is despite there being no news out of the healthcare company. But with Healthscope going into administration yesterday, it is possible that some investors are concerned about the state of the healthcare sector in Australia. Following today's decline, Healius shares are now down over 40% since 7 May. At one stage today, Healius' share price hit an all-time low of 90 cents.

Nufarm Ltd (ASX: NUF)

The Nufarm share price is down 3.5% to $2.41. Investors have been selling this crop protection company's shares since the release of its half year results last week. Although Nufarm reported a 3% lift in revenue to $1,811 million, it recorded a disappointing 39% decline in statutory net profit after tax to $29.8 million. The Seed Technologies business dragged on its earnings, reporting a 71% decline in underlying EBIT to $15.9 million. In response, management revealed that it is now reviewing the business. This includes a potential divestment.

Propel Funeral Partners Ltd (ASX: PFP)

The Propel Funeral Partners share price is down 5% to $4.34. This morning, this funerals company released guidance for FY 2025 ahead of its appearance at an investor conference. Management revealed that it expects revenue of $220 million to $225 million and operating EBITDA of $54 million to $56 million. The latter compares to operating EBITDA of $55.4 million in FY 2024. This reflects natural fluctuations in industry death volumes. In other news, the company released a succession update. This follows the decision of managing director and co-founder, Albin Kurti, to retire on 31 August after 14 years. Propel advised that the board is well advanced in implementing its succession plan. As a result, an announcement regarding future leadership is expected by 30 June.

The post Why Aspen, Healius, Nufarm, and Propel shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Healius Ltd (ASX: HLS)

The Healius share price is down over 26% to $1.13. The catalyst for this has been the healthcare company's shares going ex-dividend this morning for its upcoming special dividend. Earlier this week, the company revealed that it is returning $300 million to shareholders through a fully franked special dividend of 41.3 cents per share. This follows the completion of the sale of Lumus Imaging to funds managed by Affinity Equity Partners. Eligible shareholders can now look forward to receiving this massive dividend in two weeks on 23 May.

Light & Wonder Inc (ASX: LNW)

The Light & Wonder share price is down a further 4% to $127.58. Investors have been selling this gaming technology company's shares since the release of its first quarter update this week. Light & Wonder posted a 2.8% increase in total revenue to US$774 million for the quarter, which fell short of the consensus estimate of US$805 million. One positive, though, is that management reaffirmed its guidance for consolidated AEBITDA of US$1.4 billion for FY 2025.

REA Group Ltd (ASX: REA)

The REA Group share price is down over 1% to $246.95. This follows the release of the property listings company's third quarter update this morning. For the three months ended 31 March, REA Group reported a 12% increase in revenue to $374 million and a 12% lift in EBITDA. However, the latter was a touch short of expectations. In response to the update, the team at Goldman Sachs commented: "REA delivered an inline 3Q25 update, with Sales/EBITDA +12%/+15% vs. pcp and +0%/-2% vs. GSe."

Regis Resources Ltd (ASX: RRL)

The Regis Resources share price is down 2% to $4.76. Investors have been selling this gold miner's shares following a pullback in the gold price overnight. Traders were selling down the precious metal after the US and UK signed a trade deal. This has sparked hopes that more deals may be signed. It isn't just Regis Resources that is falling in the gold sector today. The S&P/ASX All Ordinaries Gold index is down 2.1% at the time of writing.

The post Why Healius, Light & Wonder, REA Group, and Regis Resources shares are falling today appeared first on The Motley Fool Australia.